Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Inogen Inc (INGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release is made by and between George Parr and Inogen, Inc. as of July 31, 2023 . WHEREAS, Employee signed an At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement with the Company dated April 5, 2021 ; WHEREAS, Employee has been employed at-will by the Company pursuant to the terms and conditions of the Employment Agreement and other agreements completed on his first day of employment on April 12, 2021; WHEREAS, Employee previously was granted awards of some or all of stock options, restricted stock, restricted stock units, performance restricted stock, and performance stock units in each case, that are outstanding as of the date hereof subject to the terms and conditions of the applica..."
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Consolidated Statements of Comprehensive Loss Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 Revenue Sales revenue $ 68,343 $ 89,291 $ 124,230 $ 156,693 Rental revenue 15,292 14,085 31,567 27,068 Total revenue 83,635 103,376 155,797 183,761 Cost of revenue Cost of sales revenue 42,028 50,661 75,992 90,161 Cost of rental revenue, including depreciation of $3,238 and $2,720 for the three months ended and $6,316 and $5,358 for the six months ended, respectively 7,563 6,457 15,028 12,336 Total cost of revenue 49,591 57,118 91,020 102,497 Gross profit 34,044 46,258 64,777 81,264 Operating expense Research and development 4,293 6,064 9,637 11,428 Sales and marketing 26,906 30,388 55,347 58,427 General and administrative 14,613 12,682 33,476 27,871 Total operating expe..."
07/31/2023 8-K Quarterly results
07/24/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/18/2023 8-K Quarterly results
07/13/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financia...
Docs: "10 JULY 2023 Between Mr. Adrien MITHALAL Mr. Jean-Sébastien LANTZ Mrs. Anne REISER CAAP CREATION SOCIETE DE CAPITAL RISQUE PROVENCALE ET CORSE REGION SUD INVESTISSEMENT Mérieux Participations 2 Relyens Innovation Santé the holders of Exercisable Securities listed in Schedule A As the Sellers And Inogen, Inc. As the Purchaser In the presence of Physio-Assist As the Company SHARE PURCHASE AGREEMENT",
"TERMS AND CONDITIONS OF CONVERTIBLE BONDS"
07/10/2023 SC 13G/A VANGUARD GROUP INC reports a 6.4% stake in Inogen Inc.
07/07/2023 SC 13G/A BlackRock Inc. reports a 7.5% stake in INOGEN INC
06/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/30/2023 SD Form SD - Specialized disclosure report:
05/11/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/04/2023 8-K Quarterly results
04/18/2023 ARS Form ARS - Annual Report to Security Holders:
04/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/22/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda"
02/24/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 8-K Quarterly results
Docs: "Inogen Announces Fourth Quarter and Full Year 2022 Financial Results Fourth Quarter Year-over-Year Revenue Growth of 15.3% Full Year 2022 Year-over-Year Revenue Growth of 5.4% GOLETA, Calif., February 23, 2023 -- Inogen, Inc. , a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2022."
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 8-K Quarterly results
02/01/2023 SC 13G/A BlackRock Inc. reports a 17.5% stake in INOGEN INC
01/10/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
12/22/2022 8-K Cost Associated with Exit or Disposal Activities  Interactive Data
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
10/11/2022 SC 13G/A BROWN CAPITAL MANAGEMENT LLC reports a 11.7% stake in Inogen, Inc.
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
Docs: "Inogen Announces Second Quarter 2022 Financial Results Robust Sequential Revenue Growth Driven by Fulfilled Demand GOLETA, Calif., August 04, 2022"
06/13/2022 8-K Quarterly results
05/31/2022 SD Form SD - Specialized disclosure report:
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/21/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy